Logo image of SNY

SANOFI-ADR (SNY) Stock Overview

USA - NASDAQ:SNY - US80105N1054 - ADR

51.64 USD
+2.12 (+4.28%)
Last: 10/24/2025, 8:00:02 PM
51.08 USD
-0.56 (-1.08%)
After Hours: 10/24/2025, 8:00:02 PM

SNY Key Statistics, Chart & Performance

Key Statistics
Market Cap125.85B
Revenue(TTM)67.89B
Net Income(TTM)13.81B
Shares2.44B
Float2.18B
52 Week High60.12
52 Week Low44.62
Yearly Dividend2.23
Dividend Yield4.54%
EPS(TTM)4.4
PE11.74
Fwd PE10.2
Earnings (Next)10-24 2025-10-24/bmo
IPO2002-07-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SNY short term performance overview.The bars show the price performance of SNY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

SNY long term performance overview.The bars show the price performance of SNY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 10 15

The current stock price of SNY is 51.64 USD. In the past month the price increased by 13.39%. In the past year, price decreased by -4.97%.

SANOFI-ADR / SNY Daily stock chart

SNY Latest News, Press Relases and Analysis

SNY Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 51.11 781.26B
JNJ JOHNSON & JOHNSON 18.34 458.55B
AZN ASTRAZENECA PLC-SPONS ADR 18.76 258.24B
NVS NOVARTIS AG-SPONSORED ADR 14.73 252.36B
NVO NOVO-NORDISK A/S-SPONS ADR 13.65 235.32B
MRK MERCK & CO. INC. 11.36 218.53B
PFE PFIZER INC 7.3 140.77B
GSK GSK PLC-SPON ADR 9.65 86.97B
BMY BRISTOL-MYERS SQUIBB CO 6.51 89.21B
ZTS ZOETIS INC 23.46 64.68B
TAK TAKEDA PHARMACEUTIC-SP ADR 50.04 44.25B
HLN HALEON PLC-ADR 18.88 41.19B

About SNY

Company Profile

SNY logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI-ADR

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE 75008 FR

CEO: Paul Hudson

Employees: 82878

SNY Company Website

SNY Investor Relations

Phone: 33153774000

SANOFI-ADR / SNY FAQ

What does SNY do?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


What is the current price of SNY stock?

The current stock price of SNY is 51.64 USD. The price increased by 4.28% in the last trading session.


Does SANOFI-ADR pay dividends?

SANOFI-ADR (SNY) has a dividend yield of 4.54%. The yearly dividend amount is currently 2.23.


What is the ChartMill technical and fundamental rating of SNY stock?

SNY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists SNY stock?

SNY stock is listed on the Nasdaq exchange.


What is the GICS sector and industry of SNY stock?

SANOFI-ADR (SNY) operates in the Health Care sector and the Pharmaceuticals industry.


What is the market capitalization of SNY stock?

SANOFI-ADR (SNY) has a market capitalization of 125.85B USD. This makes SNY a Large Cap stock.


SNY Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SNY. When comparing the yearly performance of all stocks, SNY is a bad performer in the overall market: 68.66% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SNY Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to SNY. While SNY has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNY Financial Highlights

Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 4.4. The EPS decreased by -2.2% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.35%
ROA 11.05%
ROE 19.73%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-8.09%
Sales Q2Q%-6.99%
EPS 1Y (TTM)-2.2%
Revenue 1Y (TTM)6.45%

SNY Forecast & Estimates

29 analysts have analysed SNY and the average price target is 63.76 USD. This implies a price increase of 23.48% is expected in the next year compared to the current price of 51.64.

For the next year, analysts expect an EPS growth of 4.12% and a revenue growth -0.42% for SNY


Analysts
Analysts81.38
Price Target63.76 (23.47%)
EPS Next Y4.12%
Revenue Next Year-0.42%

SNY Ownership

Ownership
Inst Owners47.5%
Ins Owners0.01%
Short Float %0.19%
Short Ratio1.26